The invention relates to a pharmaceutical combination, which modifies the pharmaceutical effect of the beta-receptor blockers, has new pharmaceutical effects and reduced side effects. More particularly, the pharmaceutical combination of the invention consists of a first pharmaceutical composition containing a beta-receptor blocker as active ingredient, and a second pharmaceutical composition containing a hydroximic-acid derivative as active ingredient. An object of the present invention is to improve the therapeutic effect of beta-receptor blockers.
